Micro Assays for HemATology Malignancies Antibody Treatment

NCT07018310 | Not Yet Recruiting

• 2 other identifiers: RCAPHM25_01452025-A01044-45
• Study Type: interventional
• Target: 166
• Locations: 1 country
• Sites: 1

Brief Summary

Hematological malignancy is a disease of the blood. In some cases, this pathology requires therapeutic management, which is not necessarily the case for you. Nevertheless, to improve the management of patients who need it, we are conducting research to assess the state of your immune system. Indeed, the role of the immune system is not limited to controlling infections, but is also important in controlling the proliferation of cancer cells, in hematology as in other types of cancer. Your immune system can play a spontaneous anti-tumor control role, but some so-called "immunotherapy" treatments aim to destroy cancer cells by stimulating the immune system, restoring its capabilities, and directing the immune response against tumor cells. For this immunotherapy treatment to be effective, since it uses your own immune cells (in most cases), these cells must be in a state to respond and be able to destroy the tumor. It is this ability to activate immune cells that is tested in this research protocol, using a simple test that could in future be used in routine clinical practice. But to understand why these immune cells don't work, we will also have to carry out genetic tests to analyze the various molecules that could interfere with the immune response, and try to inhibit the molecules that prevent the immune response.

Conditions

Hematological Malignancy

Outcome Measures

Primary Outcomes (1)

• Percentages of immune effectors

  Percentages of immune effectors responding to stimulation, assessed in patients with hematological malignancies

  At the enrollement in the study

Secondary Outcomes (1)

• Activation percentages (cytometry) vs. polymorphism expression percentage (molecular biology)

  At the enrollement

Study Arms (1)

blood sampling

EXPERIMENTAL

blood sampling in patients with hematological malignancies

Other: blood sampling

Interventions

blood sampling OTHER

Additional blood sampling as part of routine care

blood sampling

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or Female over 18 years of age
• Patient with a hematological malignancy likely to benefit from immunotherapy (in any form; at the discretion of the referring physician)
• Before the start of 1st-line treatment, successive lines or before autograft (chemotherapy-free for at least 4 weeks in these cases).
• Patient has received information about the study and has not expressed opposition.
• Patient who is a beneficiary or entitled beneficiary of a social security scheme

You may not qualify if:

• Subjects covered by articles L1121-5 to 1121-8 of the French Public Health Code, i.e. :
• Persons deprived of their liberty by judicial or administrative decision
• Persons subject to psychiatric monitoring under articles L3112-1 and L3113-1 who are not covered by the provisions of article L1121-8
• Minors
• Adults under legal protection or unable to express their consent.
• A person who cannot read and understand the French language well enough to be able to consent to take part in research.

Sponsors & Collaborators

• Assistance Publique Hopitaux De Marseille: lead

Study Sites (1)

Assisitance Publique Hôpitaux de Marseille

Marseille, 13005, France

Location

MeSH Terms

Conditions

Hematologic Neoplasms

Interventions

Blood Specimen Collection

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases

Intervention Hierarchy (Ancestors)

Specimen Handling; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Punctures; Surgical Procedures, Operative; Investigative Techniques

Central Study Contacts

Régis Costello Pr

CONTACT

0491435817; promotion.interne@ap-hm.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 4, 2025
• First Posted: June 12, 2025
• Study Start: January 1, 2026
• Primary Completion (Estimated): January 1, 2029
• Study Completion (Estimated): January 1, 2029
• Last Updated: November 20, 2025

Record last verified: 2025-11

Locations

FR (1)